Peplin trading halted
Tuesday, 05 October, 2004
Brisbane based Peplin Biotech (ASX:PEP) has called a halt to trading shares on the ASX for at least a week, telling shareholders to expect a major announcement.
The company told the ASX that its managing director Michael Aldridge was travelling overseas to conduct "important negotiations" in relation to the company's anti-cancer products, and expected to be able to either make a price sensitive announcement or reconsider the trading halt in one week.
Peplin was recently granted a broad US patent covering lead drug PEP005 and related compounds for anti-cancer applications over and above its existing patents covering the compound as a treatment for skin cancer. The latter is the subject of a US$23 million collaboration and licence agreement with Allergan, and the drug is currently in Phase I/II clinical trials.
Before the halt was called, the company's shares were trading at AUD$0.71.
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
